Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue performed strongly across all businesses. Profit also performed steadily as a result of negotiations over the prices of various purchased items, including raw materials, and continued productivity improvement initiatives in each business division. In March, particularly in the sanitary testing equipment business, the company also received orders believed to have been driven by concerns over soaring raw material prices and shortages of supplies resulting from heightened tensions in the Middle East. In addition, after carefully reviewing the recoverability of deferred tax assets, the company wrote them down and recorded an income tax adjustment expense of ¥42 million in its consolidated financial statements.
An income tax adjustment expense of ¥42 million was recorded in the consolidated financial statements following the write-down of deferred tax assets.
| Item | Details |
|---|---|
| Net Sales | ¥3,300 million → ¥3,357 million（+1.7%） |
| Operating profit | ¥170 million → ¥204 million（+20.5%） |
| Ordinary income | ¥170 million → ¥209 million（+23.2%） |
| Profit attributable to owners of the parent | ¥100 million → ¥141 million（+41.6%） |
| Net income per share | 22.62 yen → 32.03 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Fiscal year ended March 2025: revenue ¥3,201 million, operating profit ¥80 million, ordinary profit ¥64 million, profit attributable to owners of the parent ¥40 million, and basic earnings per share ¥9.09 |
| Reason for the revision | Revenue performed strongly across all businesses. Profit also performed steadily as a result of negotiations over the prices of various purchased items, including raw materials, and continued productivity improvement initiatives in each business division. In March, particularly in the sanitary testing equipment business, the company also received orders believed to have been driven by concerns over soaring raw material prices and shortages of supplies resulting from heightened tensions in the Middle East. In addition, after carefully reviewing the recoverability of deferred tax assets, the company wrote them down and recorded an income tax adjustment expense of ¥42 million in its consolidated financial statements. |
| Details and amount of extraordinary loss | An income tax adjustment expense of ¥42 million was recorded in the consolidated financial statements following the write-down of deferred tax assets. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited strong revenue performance across its businesses and steady profit performance resulting from continued negotiations over the prices of raw materials and other purchased items, as well as ongoing productivity improvement initiatives in each business division. In March, particularly in the sanitary testing equipment business, the company also received orders believed to have been driven by concerns over soaring raw material prices and shortages of supplies resulting from heightened tensions in the Middle East. The company also stated that, after carefully reviewing the recoverability of deferred tax assets, it wrote them down and recorded an income tax adjustment expense of ¥42 million.